Summary
BeOne Medicines Ltd. (ONC) has filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, with an amendment filed on February 28, 2025, to correct an inadvertent omission of a signature. This filing indicates ONC is a large accelerated filer and has undergone attestation of its internal control over financial reporting under Section 404(b) of SOX. The company is not a shell company, and as of June 28, 2024, its non-affiliate market capitalization was approximately $8.7 billion. The report also details the outstanding share structure, with over 1.38 billion ordinary shares outstanding, including ADSs and RMB shares. The primary purpose of this amendment is administrative, ensuring the proper execution of the original filing. Investors should note that no new financial data or operational updates are introduced by this specific amendment. The core financial and operational information from the original February 27, 2025, filing remains relevant for understanding the company's performance and position, with the incorporation by reference of portions of its definitive proxy statement for Part III disclosures.
Financial Highlights
50 data points| Revenue | $3.81B |
| Gross Profit | $3.22B |
| R&D Expenses | $1.95B |
| SG&A Expenses | $1.83B |
| Operating Expenses | $3.78B |
| Operating Income | -$568.20M |
| Interest Expense | $46.89M |
| Net Income | -$644.79M |
| EPS (Basic) | $-0.47 |
| EPS (Diluted) | $-0.47 |
| Shares Outstanding (Basic) | 1.37B |
| Shares Outstanding (Diluted) | 1.37B |
Key Highlights
- 1Company is a large accelerated filer, signifying substantial public float and market capitalization.
- 2Internal control over financial reporting has been attested to by an independent registered public accounting firm under SOX 404(b).
- 3Not a shell company, indicating ongoing operations and business activities.
- 4As of June 28, 2024, non-affiliate market capitalization was approximately $8.7 billion.
- 5Over 1.38 billion ordinary shares outstanding as of February 14, 2025, including ADSs and RMB shares.
- 6Filing is an amendment to correct a signature omission, not to update financial or operational data.
- 7Portions of the company's definitive proxy statement will be incorporated by reference into Part III.